PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: Phase 2 Synovial Fluid Biomarker Study Update, page-32

  1. 2,143 Posts.
    lightbulb Created with Sketch. 576
    You're 100% correct.

    I wanted topline readout results from the 008 study tomorrow. Because they promised it yesterday (Q3 2021) and only today they are telling me the trial is over double length of duration because they mismanaged it.

    I'll give you that.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.